1. Home
  2. CRSP vs SLNO Comparison

CRSP vs SLNO Comparison

Compare CRSP & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • SLNO
  • Stock Information
  • Founded
  • CRSP 2013
  • SLNO 1999
  • Country
  • CRSP Switzerland
  • SLNO United States
  • Employees
  • CRSP 393
  • SLNO N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • CRSP Health Care
  • SLNO Health Care
  • Exchange
  • CRSP Nasdaq
  • SLNO Nasdaq
  • Market Cap
  • CRSP 3.3B
  • SLNO 3.2B
  • IPO Year
  • CRSP 2016
  • SLNO 2014
  • Fundamental
  • Price
  • CRSP $35.62
  • SLNO $76.78
  • Analyst Decision
  • CRSP Buy
  • SLNO Strong Buy
  • Analyst Count
  • CRSP 17
  • SLNO 9
  • Target Price
  • CRSP $74.53
  • SLNO $103.33
  • AVG Volume (30 Days)
  • CRSP 2.0M
  • SLNO 955.8K
  • Earning Date
  • CRSP 05-06-2025
  • SLNO 05-07-2025
  • Dividend Yield
  • CRSP N/A
  • SLNO N/A
  • EPS Growth
  • CRSP N/A
  • SLNO N/A
  • EPS
  • CRSP N/A
  • SLNO N/A
  • Revenue
  • CRSP $37,675,000.00
  • SLNO N/A
  • Revenue This Year
  • CRSP $51.35
  • SLNO N/A
  • Revenue Next Year
  • CRSP $282.16
  • SLNO N/A
  • P/E Ratio
  • CRSP N/A
  • SLNO N/A
  • Revenue Growth
  • CRSP N/A
  • SLNO N/A
  • 52 Week Low
  • CRSP $30.04
  • SLNO $36.93
  • 52 Week High
  • CRSP $67.88
  • SLNO $80.91
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 44.74
  • SLNO 65.28
  • Support Level
  • CRSP $33.03
  • SLNO $72.23
  • Resistance Level
  • CRSP $39.38
  • SLNO $80.99
  • Average True Range (ATR)
  • CRSP 1.81
  • SLNO 3.06
  • MACD
  • CRSP -0.19
  • SLNO -0.37
  • Stochastic Oscillator
  • CRSP 33.64
  • SLNO 64.59

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Share on Social Networks: